Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Anemia 33Neoplasms 14Lymphoma, Large B-Cell, Diffuse 6Breast Neoplasms 6Lymphoma 5Neoplasms, Plasma Cell 4Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Mycosis Fungoides 3Monoclonal Gammopathy of Undetermined Significance 3Lymphoproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Follicular 3Lung Neoplasms 3Leukemia, Prolymphocytic 3Leukemia, Large Granular Lymphocytic 3Leukemia 3Immunoglobulin Light-chain Amyloidosis 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Hematologic Neoplasms 3Prostatic Neoplasms 2

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × Darbepoetin alfa × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡